BAVA:VIE
Bavarian Nordic A/S
€ 32.08
arrow_upward
+1.84%(+0.58) 1D
10-р сарын 12, 13:00:35 (GMT+2) · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
€ 31.48
High
€ 32.10
Low
€ 31.48
Mkt. cap
2.82 тэрбум
Avg. vol.
17.00
Volume
0.00
52-wk high
€ 32.47
52-wk low
€ 22.96
No. of employees
2 мян
Open
€ 31.48
High
€ 32.10
Low
€ 31.48
Mkt. cap
2.82 тэрбум
Avg. vol.
17.00
Volume
0.00
52-wk high
€ 32.47
52-wk low
€ 22.96
No. of employees
2 мян
News stories
From web sources and news partners
PR Newswire
·
28 минутын өмнө
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
Stock Titan
·
23 минутын өмнө
If the deal closes, Steve Wozniak-founded EFFORCE could bring carbon-credit trading within TROOPS' reach.
PR Newswire UK
·
43 минутын өмнө
SSA Commissioner Headlines Columbus Day at the NYSE: NYSE Content Update
Seeking Alpha
·
1 цагийн өмнө
Don't Be Afraid Of Midterms - Stay Bullish (NYSEARCA:SPY)
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1.91 мян
Founded1992 оны 7-р сарын 1
Headquarters-
Sector-
Websitebavarian-nordic.com